Advaxis (ADXS) Approved for $2.7M NJEDA NOL Program Tax Credit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program
October 13, 2016 8:00 AM EDTPRINCETON, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical stage biotechnology company developing cancer immunotherapies, has received preliminary approval for a $2.7 million tax credit from the New Jersey Economic Development Authoritys (NJEDA) New Jersey Technology Business Tax Certificate Transfer (NOL) program. The company anticipates it will be able to transfer this credit and receive... More
